Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
Top Page
Nautilus Biotechnolgy
(NASDAQ:NAUT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$2.50
▲(3.31% Upside)
Action:ReiteratedDate:02/27/26
The score is held back primarily by weak financial performance (pre-revenue, ongoing losses and cash burn with equity erosion risk). Partly offsetting this are constructive technical momentum signals and a moderately positive earnings-call outlook highlighting progress, validation, and a defined commercialization timeline—though near-term revenue remains small and 2026 burn is guided higher.
Positive Factors
Proprietary Voyager platform
The Voyager instrument provides a durable technical moat: a novel benchtop system designed to map billions of intact proteins and proteoforms, giving Nautilus a tangible product ahead of broad GA. This structural IP and tangible platform reduce scientific execution risk and underpin future instrument+consumable recurring revenue once commercialized.
External scientific validation & collaborations
Independent biological validation from respected research partners demonstrates differentiated assay capability and scientific credibility. Such third‑party validation lowers adoption barriers, supports downstream partnerships and publications, and materially increases the odds that Voyager and its assays earn trust among core research and pharma customers over the medium term.
Improved cash position and expense discipline
Reduced operating spend and a cash balance providing runway through 2027 materially lower immediate financing pressure. Demonstrated cost discipline and improved burn rate give management time to execute Early Access, instrument preorders, and initial installs, increasing odds the company reaches commercial inflection without immediate dilution.
Negative Factors
Zero reported revenue; persistent losses
Nautilus remains pre‑revenue with multi‑year net losses, meaning the business model and recurring consumables economics are unproven. Continued operating losses erode equity and create structural financing needs; without demonstrated revenue, commercial scale and margin sustainability remain speculative over the next several quarters.
Planned 2026 spending step‑up increases funding risk
Management expects a meaningful increase in 2026 operating expense and cash burn versus 2025, which tightens the cash runway profile and raises the probability of additional external funding. Higher near‑term investment is strategic but increases dilution and execution risk if commercial traction lags assumptions.
No sales organization; commercialization execution risk
Absent an established sales force and commercialization infrastructure, converting Early Access interest into instrument orders and recurring consumables revenue will be slow and execution‑sensitive. Building commercial capability is time‑consuming and raises the risk that planned 2026‑2027 revenue ramps slip or underdeliver versus milestones.
Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$306.29M
Dividend YieldN/A
Average Volume (3M)394.63K
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue GrowthN/A
EPS Growth11.15%
CountryUS
Employees134
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding126,564,476
10 Day Avg. Volume378,207
30 Day Avg. Volume394,629
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-4.74
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-50.01
Enterprise Value/Ebitda-6.15
Forecast
1Y Price Target
$4.00Price Target Upside65.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$1.50M
Nautilus Biotechnolgy Business Overview & Revenue Model
Company DescriptionNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
How the Company Makes MoneyNautilus Biotechnology generates revenue primarily through the commercialization of its proteomics platform. The company offers its technology to pharmaceutical companies, academic institutions, and research organizations, which use it to conduct detailed protein analysis. Key revenue streams include the sale of instruments, consumables, and related services required to operate the platform. Additionally, Nautilus may engage in strategic partnerships and collaborations with other entities in the biotech and pharmaceutical industries, which can provide further revenue through joint research projects, licensing agreements, and milestone payments based on the successful achievement of specific research or development goals.
Nautilus Biotechnolgy Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 05, 2026
Earnings Call Sentiment Positive
The call emphasized meaningful technical progress, strong external validation, the successful public debut of the Voyager instrument, the early launch of an Early Access Program (Tau assay) and disciplined expense reductions that improved cash burn and extended runway through 2027. Offsetting these positives are limited near-term revenue (modest 2026 services revenue targeted at ~$0.5M), no current sales organization, and a planned increase in 2026 operating expenses and cash burn as the company invests to advance commercialization. On balance, the developments point to a company transitioning from development to early customer engagement with tangible validation and a clear commercialization timeline, though revenue and commercial execution risks remain in the near term.Q4-2025 Updates
Positive Updates
Voyager Instrument Debut and Positive Community Reception
Public unveiling of the Nautilus Voyager instrument at US HUPO with highly positive feedback from researchers; provided the proteomics community its first tangible view of the system and reinforced interest from prospective customers.
Early Access Program Launched Ahead of Schedule
Iterative Mapping Early Access Program launched in January earlier than planned, beginning with the Tau proteoform assay; enables partners to submit samples, receive data and provide feedback to inform workflows and future commercial readiness (early engagements not expected to drive near-term revenue).
External Collaborations and Biological Validation
Strong external validation from collaborations with Buck Institute and Allen Institute producing biologically compelling tau proteoform data (differences across brain regions and disease severity) presented at World HUPO and US HUPO; supports claim of unique biological insight unavailable from conventional proteomics.
New Grant-Funded Collaboration for Alpha-Synuclein
18-month collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation focused on alpha-synuclein proteoforms; $1.6M total funding with approximately $1.2M to Nautilus to be recognized as work progresses over 2026-2027, extending platform into Parkinson's disease applications.
Technical Progress on Assays and Platform
Progress on broadscale assay configuration change with initial data from new chips encouraging; largest-scale experiments yet demonstrated decoding of proteins from complex mixtures (including cell lysates); fabrication improvements and indications of increased on-target binding.
Tau Proteoform Assay Ready for Early Access
Verification and validation of Tau proteoform assay largely complete and meeting requirements for accuracy, dynamic range, reproducibility and stability; on schedule to begin processing Early Access Program samples by end of Q1 2026.
Operational Discipline and Reduced Spend
Fiscal 2025 cost reductions: Q4 operating expenses $15.4M (down 23% YoY vs prior year period), full-year operating expenses $66.8M (down 18% YoY). R&D expenses $41.1M (down $9.4M or 19% YoY) and G&A $25.7M (down $5.3M or 17% YoY).
Improved Cash Position and Lower Burn
Ending cash, cash equivalents and investments of $156.1M; cash burn in 2025 was $50.2M, down from $57.8M in 2024 (approximately a 13% reduction). Company expects cash runway to extend through 2027 under current plan.
Negative Updates
Limited Near-Term Revenue and Delayed Commercial Ramp
Early Access engagements are not expected to drive material revenue in 2026; management projects modest services revenue (targeting ~ $0.5M for 2026) with primary instrument and consumables revenue expected to ramp in 2027 when instrument placements begin.
No Sales Organization Today
Company currently has zero salespeople and is only beginning to build a focused commercial team this quarter, which constrains funnel conversion and delays broad commercial engagement ahead of planned late-2026 preorder launch.
Planned Increase in 2026 Operating Expense and Cash Burn
Management expects total operating expenses to rise ~15%–20% in 2026 and forecasts full-year 2026 cash burn of $65M–$70M, representing a notable step-up from 2025 levels and increasing near-term funding requirements.
Remaining Technical Optimization Required
Although progress is strong, work remains to optimize assay stability (chips stable over hundreds of cycles), further increase on-target binding and minimize off-target binding; these are optimization rather than novel-engineering issues but are necessary to scale broadly.
Revenue Concentration Risk and Timing Dependence
Future recurring revenue is dependent on instrument placements driving consumables; general availability for Voyager and core assays is targeted for late 2026/early 2027 (broadscale capabilities GA expected H1 2027), creating timing risk for the revenue ramp.
Workforce Reductions Impact and One-Time Savings
2025 expense reductions included savings from a reduction in force (lower salaries/benefits) and lower stock-based compensation; while these improved near-term cash use, they also reflect organizational changes that may affect capacity and require careful rebuild for commercial expansion.
Company Guidance
Nautilus provided clear financial and commercial guidance: it finished the quarter with $156.1M in cash, reported 2025 cash burn of $50.2M (down from $57.8M in 2024), FY2025 operating expenses of $66.8M (‑18% YoY) with R&D $41.1M (‑19%) and G&A $25.7M (‑17%), and Q4 operating expenses of $15.4M (‑23% YoY); for 2026 the company expects total operating expenses to rise ~15–20% and full‑year cash burn of $65–70M, which it says supports a cash runway through 2027; revenue guidance calls for modest services revenue later in 2026 (management targets roughly $0.5M for 2026) plus recognition of Michael J. Fox Foundation-funded work (~$1.2M to Nautilus over ~18 months, with a portion in 2026 and the remainder in 2027), while commercial milestones include Early Access (Tau) sample processing by end of Q1 2026, preorders late 2026, instrument installations beginning early 2027, GA at launch of Voyager plus Tau and a second proteoform assay, and broadscale GA in H1 2027.Nautilus Biotechnolgy Financial Statement Overview
Summary
Financial profile is weak: zero reported revenue across the periods provided, persistent large net losses, and consistently negative operating/free cash flow indicating ongoing cash burn and reliance on external funding. The balance sheet is a relative support with low leverage and positive equity, but equity/assets have eroded over time, keeping dilution/financing risk elevated.Income Statement
The income statement remains very weak, with zero reported revenue across all annual periods provided and persistent, sizable net losses (roughly $50–71M per year). Losses widened versus 2020 and have stayed elevated, indicating the business is still in an investment/burn phase with no demonstrated path to operating leverage in the reported numbers. A modest positive is that the 2025 net loss improved versus 2024, but profitability is still far from break-even.18
Very Negative
Balance Sheet
The balance sheet is mixed. Leverage looks manageable with debt-to-equity staying relatively low in recent years (about 0.08–0.19), and equity remains positive through 2025. However, stockholders’ equity and total assets have declined materially from 2021–2022 levels, consistent with ongoing losses eroding the capital base. Returns on equity are consistently negative (except 2020, which is distorted by negative equity), highlighting continued value dilution risk if losses persist.52
Neutral
Cash Flow
Cash flow quality is pressured by sustained cash burn: operating cash flow and free cash flow are negative every year shown. Free cash flow burn increased in 2025 versus 2024, and free cash flow growth is negative, signaling worsening near-term cash usage. A relative positive is that free cash flow is broadly tracking net loss (free cash flow roughly in line with net income), suggesting losses are not heavily driven by non-cash accounting, but the company still relies on external funding to sustain operations.26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -6.46M | -6.35M | -5.71M | -3.42M | -2.84M |
| EBITDA | -52.54M | -64.43M | -74.30M | -54.51M | -47.47M |
| Net Income | -59.00M | -70.78M | -63.67M | -57.92M | -50.31M |
Balance Sheet | |||||
| Total Assets | 191.11M | 242.74M | 305.56M | 350.05M | 398.45M |
| Cash, Cash Equivalents and Short-Term Investments | 103.41M | 129.89M | 173.42M | 184.47M | 345.73M |
| Total Debt | 30.02M | 30.48M | 34.63M | 30.33M | 30.03M |
| Total Liabilities | 34.14M | 34.01M | 40.21M | 35.13M | 34.87M |
| Stockholders Equity | 156.97M | 208.73M | 265.35M | 314.92M | 363.58M |
Cash Flow | |||||
| Free Cash Flow | -51.97M | -61.27M | -54.15M | -48.13M | -41.51M |
| Operating Cash Flow | -50.70M | -59.15M | -51.71M | -45.81M | -39.24M |
| Investing Cash Flow | 35.22M | 66.25M | -43.73M | -25.74M | -138.96M |
| Financing Cash Flow | 214.00K | 1.14M | 368.00K | 562.00K | 327.45M |
Nautilus Biotechnolgy Technical Analysis
Neutral
2.42
Price Trends
2.15
Positive
1.88
Positive
1.32
Positive
Market Momentum
0.16
Negative
51.62
Neutral
47.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Neutral. The current price of 2.42 is above the 20-day moving average (MA) of 2.37, above the 50-day MA of 2.15, and above the 200-day MA of 1.32, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 51.62 is Neutral, neither overbought nor oversold. The STOCH value of 47.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NAUT.
Nautilus Biotechnolgy Risk Analysis
Nautilus Biotechnolgy disclosed 69 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nautilus Biotechnolgy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $175.08M | -1.41 | -63.45% | ― | ― | 63.31% | |
54 Neutral | $190.20M | -1.42 | -85.93% | ― | ― | -60.99% | |
54 Neutral | $103.68M | -1.34 | -25.74% | ― | 13.77% | -4.76% | |
52 Neutral | $306.29M | -5.18 | -32.00% | ― | ― | 11.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $23.22M | -0.37 | ― | ― | -33.00% | 54.91% |
* Healthcare Sector Average
NAUT
Nautilus Biotechnolgy
2.42
1.18
95.16%
VTGN
VistaGen Therapeutics
0.59
-1.90
-76.47%
KLRS
Kalaris Therapeutics
10.46
0.44
4.39%
SEER
Seer
1.72
-0.34
-16.50%
ABOS
Acumen Pharmaceuticals
3.14
1.99
173.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.